SCHEMBL3101575

SCHEMBL3101575

Cc1cc(-c2ccccc2)sc1C(Oc1ccc(C(=O)O)cc1)C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.38
KDR P35968 1/20 0.37
KDM4E B2RXH2 2/20 0.36
CHEK1 O14757 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
ALOX5 P09917 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
GAA P10253 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPK11 Q15759 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3101127 0.91 KDM4E (0.42) KMT2ASMN1; SMN2HPGDNPC1RAB9A
SCHEMBL3111621 0.88 SMN1; SMN2 (0.40) RXRARXRBKMT2ASMN1; SMN2HPGD
SCHEMBL3113661 0.85 GCG (0.52) SMN1; SMN2HPGDNPC1RAB9ANPSR1
SCHEMBL3095425 0.85 KDM4E (0.38) SMN1; SMN2HPGDNPC1RAB9ANPSR1
SCHEMBL3110114 0.79 RCE1 (0.45) RXRARXRBKMT2ANPC1RAB9A
SCHEMBL3093701 0.79 SMN1; SMN2 (0.41) SMN1; SMN2HPGDNPC1RAB9ANPSR1
SCHEMBL3110121 0.76 GCGR (0.56)
SCHEMBL3095546 0.75 GCGR (0.42) KMT2ASMN1; SMN2HPGDNPC1RAB9A
SCHEMBL3109620 0.73 KDM4E (0.42) KMT2ASMN1; SMN2HPGDNPC1NPSR1
SCHEMBL3110402 0.72 CHEK1 (0.37) KMT2ASMN1; SMN2NPSR1KDM4ECHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR RXRA 810/4885RXRB 827/4885KMT2A 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.